This clinical trial is focused on studying the treatment of Ulcerative Colitis, a condition that causes inflammation and sores in the digestive tract, specifically affecting the innermost lining of the large intestine and rectum. The study will evaluate a new medication known by its code name, JNJ-77242113, to see how effective and safe it is for people with moderately to severely active ulcerative colitis. Participants in the study will receive either the medication or a placebo, which is a substance with no active drug, to compare the effects.

The purpose of the study is to assess whether JNJ-77242113 can help reduce the symptoms of ulcerative colitis. The study will last for a period of 76 weeks, during which participants will be monitored for their response to the treatment. The medication will be administered in the form of a film-coated tablet taken orally. Throughout the study, participants will have regular check-ups to track their progress and any changes in their condition.

In addition to JNJ-77242113, the study will also involve other medications that are commonly used to manage ulcerative colitis, such as Mercaptopurine, Methotrexate, and Azathioprine. These medications are known to help control inflammation and immune system activity. The study aims to provide valuable information on the potential benefits of JNJ-77242113 in improving the quality of life for those living with ulcerative colitis.